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Background: The significance of definitive radiotherapy for sinonasal mucosal melanoma (SMM) is sill controvertial.
This study was to evaluate the role of high-dose proton beam therapy (PBT) in patients with SMM.
Methods: The cases of 20 patients with SMM localized to the primary site who were treated by PBT between 2006
and 2012 were retrospectively analyzed. The patterns of overall survival and morbidity were assessed.
Results: The median follow-up time was 35 months (range, 6–77 months). The 5-year overall and disease-free
survival rates were 51% and 38%, respectively. Four patients showed local failure, 2 showed regrowth of the primary
tumor, and 2 showed new sinonasal tumors beyond the primary site. The 5-year local control rate after PBT was
62%. Nodal and distant failure was seen in 7 patients. Three grade 4 late toxicities were observed in tumor-involved
optic nerve.
Conclusion: Our findings suggested that high-dose PBT is an effective local treatment that is less invasive than
surgery but with comparable outcomes.
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Sinonasal mucosal melanoma (SMM) is a rare disease ac-
counting for 0.3–2% of all malignant melanomas in North
America [1]. Its prognosis is much worse than that of cu-
taneous malignant melanoma; the overall 5-year survival
rate of patients with SMM is reported to be 34% [2]
whereas that of patients with head and neck cutaneous
melanoma is reported to be 80% [3]. Surgery has been
the main option for eradicating the disease [4-6]. However,
in a review of cases from a high-volume cancer center
in North America, recurrence of the primary disease was
observed in 50% of cases [7-9].
For patients with SMM, radiotherapy has been employed
for palliation or as adjuvant treatment for surgery. How-
ever, a nationwide survey recently performed in the United
States revealed that radiotherapy has a limited role in im-
proving overall patient survival [3]. Definitive radiotherapy* Correspondence: fuji-h@ncchd.go
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unless otherwise stated.for SMM has been applied selectively because of tumor
radioresistance and the propensity for metastases to dis-
tant organs. Furthermore, in the case of SMM, intensive
radiotherapy is only applicable to a small proportion of
patients because the tumors are frequently surrounded by
radiosensitive critical tissues, e.g., the optic nerve, cranial
nerves, and the brain stem.
Highly conformal beam delivery techniques are prom-
ising measures with which to deliver definitive high-dose
radiotherapy in patients with SMM. Intensity-modulated
radiotherapy and particle beam therapy have both been
reported to facilitate the delivery of high doses to the re-
sidual tumor while minimizing exposure to the surround-
ing normal tissues [10-14].
In a short-term analysis, the primary disease control rate
associated with high-dose conformal proton beam therapy
was reported to be promising [14]. These data propose a
definitive role for proton beam therapy; however, the ac-
tual efficacy of this treatment with escalating prescribed
dose needs to be established for long-term tumor control
and the morbidity in critical organs at the irradiated sites
needs to be evaluated. Furthermore, the significance of the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pattern of relapse needs to be analyzed with a sufficient
follow-up time. The purpose of this study therefore was
to describe the long-term course of patients undergoing
definitive high-dose PBT for localized SMM.
Patients and methods
Patients
This retrospective analysis was approved by the internal
review board of our institution. From 2006 to 2010, 20
consecutive SMM patients underwent definitive PBT at
our institution. The feasibility of surgical resection was
discussed among proficient head and neck surgeons and
proposed to the patients. Eight patients were inoperable
and others refused surgery because of irreversible im-
pairment of organs at the skull base by surgery. Written
informed consent was obtained from patients. All pa-
tients had biopsy-proven mucosal malignant melanomas.
Histological diagnoses were based on the findings of
hematoxylin and eosin staining, with confirmation using
immunostaining in some cases. An experienced patholo-
gist classified SMM cases according to the state of cellu-
lar differentiation. Differentiated cells were epithelioid,
localized to interconnected nests, and/or spindle-shaped
in a fascicular pattern. Undifferentiated cells were smaller
and characterized by an incohesive architecture. Disease
extent was evaluated using computed tomography (CT)
and magnetic resonance imaging (MRI) scans. Of 20 pa-
tients, 18 underwent fluorodeoxyglucose (FDG)-positron
emission tomography (PET) for the detection of regional
and distant lesions. Melanomas of the upper aerodigestive
tract were classified in accordance with the criteria listed
in the seventh edition of the TNM Staging System of the
Union Internationale Contre le Cancer for melanoma of
the upper aerodigestive tract. Ten of 20 tumors involved
the unilateral optic nerve. Table 1 presents the clinical
characteristics of patients.
The median time interval between diagnosis and the
start of PBT was 4.8 months (range, 0.5–56.2 months).
Nine patients had recurrent disease after local surgery be-
fore being referred to our institute. Seven patients under-
went 1–8 cycles of systemic chemotherapy before PBT.
All patients underwent definitive PBT because gross tumor
volume was observed at the start of PBT. Sixteen patients
underwent concurrent or adjuvant multi-agent chemo-
therapy consisting of dacarbazine, nimustine, and vincris-
tine or dacarbazine, nimustine, cisplatin, and tamoxifen.
The treatment period of concurrent or adjuvant chemo-
therapy was 8 months (4–12 months).
Proton beam therapy
The gross tumor volume (GTV) was defined as the gross
extent of the tumor as observed on CT or MRI images.
Areas showing elevated FDG-PET signals were alsoincluded in the GTV. The clinical target volume (CTV)
was defined as GTV with a 2–10 mm margin. Areas with
mucosal alteration and inflammatory tissue as seen on a
T2-weighted image were also included in the CTV. The
planning target volume (PTV) was defined by adding a 3-mm
margin to the GTV and CTV, referred to as the PTV(GTV)
and PTV(CTV), respectively.
A proton beam has a unique depth-dose curve, the
so-called Bragg peak and deposits a maximum energy at
a designated depth. With this physical feature, the pro-
ton beam provides highly conformal dose deposition for
SMM. The proton beam used in this study was 150 MV,
passive scattering beam. The biological effectiveness of
proton on using PBT differs from that of photons on using
conventional radiation because of this unique mechanism
of energy deposition. On considering the relative bio-
logical effect of a proton beam, the dose was reported in
grays relative biological effectiveness, Gy (RBE), which
was equivalent to the physical dose in Gy multiplied by
1.1. A hypofractionated treatment schedule of 3.5 Gy
(RBE) per fraction administered daily for a total dose of
70 Gy (RBE) in 20 fractions was applied.
Treatment planning was performed such that 90% of
the PTV(GTV) received 95% of the prescribed dose and
PTV(GTV) received more than 40 Gy. Simultaneous inte-
gral boost technique was used to deliver different dose
to two target volumes, PTV(GTV) and PTV(CTV) in single
fraction. In each treatment time, PTV(GTV) irradiated
3.5 Gy and PTV(CTV) irradiated more than 2 Gy by using
two or more field.
A constraint dose of 50 Gy (RBE) was set for the optic
nerve and chiasma except in cases of a tumor involving








Figure 1 A representative treatment plan of proton beam therapy for sinonasal mucosal melanoma. Dose distribution on trans-axial
(A, B), coronal (C), and sagittal (D) images with color scale. Colors depict the high-dose area on the gross tumor and the mid-dose area on the
clinical target volume.
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(RBE). The head and neck were immobilized using
thermoplastic shells during treatment sessions. Orthog-
onal fluoroscopy was used before every treatment session
to verify beam localization. A passive scattering proton
beam was used. The patterns of irradiated tumor response
were assessed using MRI, CT, and PET imaging, per-
formed every 3–6 months. Acute toxicities were scored
according to the National Cancer Institute (USA) Common
Toxicity Criteria version 3.0. Late toxicities were evaluated
according to Radiation Therapy Oncology Group and
European Organization for Research and Treatment of
Cancer late radiation morbidity scoring schemes.Statistical analyses
Overall survival, disease-free survival, and local control
rates were estimated using the Kaplan–Meier method.
All events were calculated from the first day of PBT to
the last day of follow-up. Local failure comprised both
progression of the primary tumor and appearance of a
new lesion at the sinonasal site after PBT. Standard errors
for estimated survival were compared using a log-rank test
for association among potential prognostic factors. A
p value of ≤0.05 was considered statistically significant. Allstatistical analyses were performed using PASW 17.0
(PASW, Chicago, Illinois).
Results
Tumor recurrence and survival
The median follow-up period was 35 months (range,
6–77 months). For all patients, the 3-year and 5-year
overall survival rates were 68% and 54%, respectively,
with a median survival time of 39 months (Figure 2A).
The 3-year and 5-year progression-free survival rates
were 60% and 52%, respectively (Figure 2B). At the time
of analysis, 10 patients were alive. Eight patients had died
due to disease progression. Four patients showed local
failure at sinonasal site: 2 patients presented with primary
tumor progression at 47 and 50 months after PBT and 2
presented with recurrence of melanoma in the sinonasal
region beyond the GTV at 19 and 24 months after PBT.
For all patients, the 3-year and 5-year actuarial local con-
trol rates were 70% and 62%, respectively (Figure 2C).
Distant metastases were observed 7 patients (liver, 3;
lung, 2; brain, 1; and intestine, 1). Three patients showed
lymph node involvement after PBT.
Differentiated morphology presenting as epithelioid and
spindle cell type cells was associated with significantly bet-
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Figure 2 Overall survival (A), disease-free survival (B), and local disease-free (C) rates of patients who underwent proton beam therapy
for sinonasal mucosal melanoma. The overall survival curves of patients with differentiated morphology were compared with those of patients
with undifferentiated morphology and other morphologies (dotted line), and cellular morphology was found to be a significant prognostic
factor (D).
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chemotherapy, FDG-PET signal level, and tumor size did
not show any significant association with survival.
Treatment toxicity
Details of acute toxicity are presented in Table 2. All
patients with mucositis were scored as having grade 1–3
severity. All patients with dermatitis, except for 1, ex-
perienced grade 1–3 severity. In addition, 1 patient
who underwent concurrent chemotherapy experienced
grade 4 thrombocytopenia. Excluding this case, overall,
the hematological toxicities were mild (of less than
grade 2 severity).Table 2 Acute toxicities of proton beam therapy
Type Grade Number (%)
Mucositis 1–2 14 (70)
3 5 (25)
Dermatitis 1–2 18 (90)
3 1 (5)
Keratitis 1–2 2 (10)
Eyelid function disorder 1–2 8 (40)
Thrombocytopenia 4 1 (5)Late toxicities of were described in Table 3. Grade 4
toxicity observed in the cohort was optic nerve disorder.
Three patients showed unilateral visual impairment after
PBT. In 2 of these patients, the optic nerve was irradi-
ated with >68 Gy and a decrease in visual function was
observed 20 and 39 months after PBT. The third patient,
whose right optic nerve was irradiated with <36 Gy
showed right visual impairment 20 months after treat-
ment. Images taken at the time revealed expansion of
the tumor and optic nerve compression. Although
tumor expansion was transient, the patient’s visual im-
pairment did not improve. The relationship between
dosing to the optic nerve and follow-up time is depicted
in Figure 3.Table 3 Late toxicities of proton beam therapy
Type Grade Number (%)
Nasal congestion 1 6
Epistaxis 1-2 3
Watering eyes 1-2 8
Osteonecrosis 2 5
Optic nerve disorder 4 3
Middle ear inflammation 2 7
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Figure 3 The dose received by the optic nerve was plotted
against the follow-up time to determine the relationship
between irradiation dose and visual impairment onset. The
filled symbols correspond to optic nerves with visual impairment.
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field. Initially, those patients suffered with the pain of af-
fected bone. However, a course of antibiotics relieved the
pain and enable to take food. Radiation-induced grade 2
otitis was observed in 7 patients; this could be controlled
with antibiotic administration in all cases. Watering eyes
due to lacrimal duct obstruction were most frequent late
adverse events.
Discussion
In this study, high-dose PBT resulted in favorable primary
disease control. Most reviews on the management of head
and neck mucosal melanoma suggest that radiotherapy
has only a minor role and is mostly used as adjuvant treat-
ment. However, it has been suggested that these treat-
ments could provide an option for eradication of primary
disease. A study of 85 carbon ion-treated cases reported a
5-year actuarial local control rate of 75% [12,13]. Short-
term analysis of PBT also showed promising outcomes
with a 3-year local control rate of 86% [14].
The current study showed that the primary disease was
controlled in all patients within 3 years. The higher pri-
mary disease control rate most likely contributed to the
improved overall survival of the cohort. The 5-year overall
survival rate achieved here is comparable with those
reported for surgery [2,8].
There are two cases developed recurrent disease outside
of primary gross disease. Although in-transit spreadingis known to be a major feature of mucosal melanoma,
we have few knowledge for detecting microscopical in-
filtration of mucosal melanoma. Recent advantage of
high sensitive imaging technology, like FDG-PET and
other more specific imaging technique or both could
be useful tool for defining irradiation target volume of
mucosal melanoma. However, defining the border of tumor
abutted brain or occulomotor is still challenging, because
the both show higher uptake of FDG. Another type of ra-
diotracer specific for melanin in melanoma cells, known as
a benzamide derivative could be useful for defining the ex-
tension of tumor arose head and neck region [15].
Comparison between treatment outcomes of carbon
ion beam and those of proton beam do not suggest appar-
ent superiority of carbon ion treatment. Reported local
control rate 3 years after carbon ion treatment ranged
from 65% to 85% [12,13]. Current study showed that local
control rate of 87% at 3 years after treatment. Better local
control rate, 75% at 5 years after carbon ion treatment has
been reported [13]. However, more censored cases with
lower long term survival rate of the study remains the un-
certainties of long term local disease control rate. Short
term analysis of carbon ion beam and proton beam imple-
mented for head and neck melanoma at same institute
showed identical local control rate at 2 years after treat-
ment [16].
Here, the analyses involved dose escalation and hypo-
fractionated schemes as well as other definitive therapies
with other particle beam therapy series. The prescribed
doses of those particle beam treatments can be con-
verted to 84–91 Gy in equivalent dose in 2 Gy fractions.
(EQD2) of a standard fractionation scheme. These are
1.2–1.5 times higher than those employed for other head
and neck tumors. Nevertheless, 2 cases of primary tumor
relapse were observed 4 years after PBT. Delayed recur-
rence of irradiated tumors needs to be recognized as a pos-
sible characteristic of high-dose radiotherapy.
Reported intensive radiotherapy for mucosal melanoma
is usually scheduled for 1–4 days/week [10-14,16]. In con-
trast, the current treatment plan involved a conventional
schedule of 5 days/week. In terms of the deposited dose at
the target, the 3.5-Gy (RBE) fraction size used here is
regarded as hypofractionated but has been reported to be
effective for eradicating mucosal melanoma. However, a
treatment planning technique known as simultaneous in-
tegrated boost (SIB) facilitates a decreased dose per each
fraction (i.e., 2 Gy (RBE) per fraction) for critical struc-
tures in the CTV. The use of the SIB technique here, even
in a hypofractionated schedule, enabled the application of
a constraint dose and an estimation of toxicity based on
the knowledge of standard daily fractionated treatment.
We encountered 2 cases of optic nerve impairment
after ablative dose delivery to the nerve. For these patients,
the intention of treatment was both eradication of the
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Therefore, differentiated doses were employed for optic
nerves. The affected optic nerve received 64 Gy, whereas
the contralateral site received <50 Gy. Thus, the primary
disease was controlled for 4-years and contralateral vision
was preserved, suggesting that this treatment is an accept-
able option for patients with unilateral optic nerve in-
volvement or those offered optic nerve transection.
The establishment of prognostic factors to identify
patients who would benefit from PBT is essential. In the
current study, differentiated cellular morphology was a
significant survival factor, However, an obvious limitation
of the current study is the small sample size. A future ana-
lysis of a large cohort of patients treated with PBT would
help reinforce the significance of cellular morphology as a
prognostic indicator.
We did not implemented prophylactic cervical lymph
node irradiation because the prophylactic treatment plays a
limited role for improvement of survival. Gilligan reported
8 cases developed lymph node recurrence among 28
patients who underwent definitive radiotherapy for
sinonasal melanoma [17]. Of eight patients, six patients
emerged with concomitant disease of primary tumor re-
currence or distant metastasis. In current study, we ob-
served three cases developed neck lymph node metastasis
among 20 cohort. Of three, two patients presented with
recurrence at primary site or other organs. One patient
without other recurrent disease was salvaged with neck
dissection.
In the present study, chemotherapy was administered
to 16 of 20 patients, which likely played a substantial
therapeutic role because a gradual decrease in tumor
markers was noted during treatment. Considering the
diverse backgrounds of patients with respect to treat-
ment modalities, the current analysis was not appropriate
for evaluating chemotherapeutic benefits. Chemotherapy-
induced cytotoxicity during and after the PBT is a
concern; however, no patients receiving chemotherapy
suffered from unexpected treatment interruptions and
only 1 case of grade 4 hematological toxicity was en-
countered. Therefore, concurrent chemotherapy was
feasible, but its significance for tumor control remains
to be determined.Conclusion
Hypofractionated high-dose PBT reported here improved
the local control rate associated with SMM. The sustained
control of the primary lesion resulted in a favorable
survival rate, comparable to that achieved by surgery
in patients with certain tumor types.Competing interests
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